Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma

NCT00299494 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00299494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00299494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
May 4, 2006
Completion date
June 2, 2014
Enrollment
119 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma